rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome.
Result: Of note, of the seven types, the following three rt
Result: We found a total of seven types of signature NS mutations in the Pol region (three types in RT, one type in the terminal protein (TP) region, two types in the spacer region and one type in the RNaseH region), of which all seven (rtN139K/H, rtM204I/V and rtI224V in RT, D16A/E/N/V in TP, S314P and F321L in Spacer and D828A/V in the RNaseH region) were rt269I signature types.
Entecavir resistance in a patient with treatment-naive HBV: A case report.
PMID: 33903819
2021
Molecular and clinical oncology
Discussion: There were 8 mutations in the RT region, rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V and rtM309K that were significantly associated with the progression of HCC in treatment-naive patients.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Result: These sites could be classified into the following groups: V191I and V207I/M were detected in cases experienced ADV treated; F221Y were found in cases experienced LAM treated; S213T, I224V and H/N238 seemed to be the sharing mutation sites of LAM, ADV and ETV.
Table:
Discussion: Among 435 patients, non-classical mutations were detected at nine sites (V191I, V207I/M, S213T, E218D, F221Y, I224V, L229V, N/H238 and R242D) with virological breakthrough and without classical mutations (Table 4).
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Abstract: Eight mutations in RT (rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V,
Method: Wu et al also investigated preexisting RT mutations potentially related to HCC in Chinese patients and identified rtI224V and rtM309K as significant risk factors for HCC (P = 0.005 and P = 0.007, respectively).
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Abstract: In addition to the common substitutions, unknown amino acid substitutions, such as rtL145 M/S, rtF151Y/L, rtR153Q, rtI224 V, rtN248H, rtS223A, rtS256C, need to be further verified.
Figure: Several other variants fluctuated at relatively high levels (ranging from 3.56% to 7.89%), including rtN248H, rtS223A, rt<
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Introduction: Pretreatment mutations (such as T38A, Y124H, D134E, N139K/H, I224V, and R242A) were defined as amino acid substitutions that have been reported among NA-naive patients but their relationships with antiviral resistance development have not been clarified yet.
Table: I224V
Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues.
Abstract: We also detected several polymorphic sites,including rtF221Y, rtS223A, rtI224V, rtN238H, rtL267Q, and rtQ271M, during the sequential treatment.